Details of the Drug

General Information of Drug (ID: DMI6E0R)

Drug Name
Midostaurin
Synonyms
PKC412; 120685-11-2; Cgp 41251; 4'-N-Benzoylstaurosporine; CGP-41251; Benzoylstaurosporine; PKC-412; RYDAPT; PKC 412; UNII-ID912S5VON; N-Benzoylstaurosporine; ID912S5VON; CHEMBL608533; CHEBI:63452; Cgp 41 251; N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide; PKC-412(Midostaurin); Midostaurin (PKC412); Midostaurin (USAN/INN); Midostaurin [USAN:INN]; CGP 41231; Rydapt (TN); CPG 41251
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Approved [1]
Systemic mastocytosis 2A21.0 Approved [2]
Chronic myelomonocytic leukaemia 2A40 Phase 2 [3], [4]
Colorectal cancer 2B91.Z Phase 1 [3], [4]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 570.6
Topological Polar Surface Area (xlogp) 4.8
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 21 hours [5]
Metabolism
The drug is metabolized via the hepatic CYP3A4 [6]
Vd
The volume of distribution (Vd) of drug is 95.2 L [7]
Chemical Identifiers
Formula
C35H30N4O4
IUPAC Name
N-[(2S,3R,4R,6R)-3-methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]-N-methylbenzamide
Canonical SMILES
C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)N(C)C(=O)C9=CC=CC=C9)OC
InChI
InChI=1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,(H,36,40)/t25-,26-,32-,35+/m1/s1
InChIKey
BMGQWWVMWDBQGC-IIFHNQTCSA-N
Cross-matching ID
PubChem CID
9829523
ChEBI ID
CHEBI:63452
CAS Number
120685-11-2
DrugBank ID
DB06595
TTD ID
D07NVU
VARIDT ID
DR01370
INTEDE ID
DR1090
ACDINA ID
D00431

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fms-like tyrosine kinase 3 (FLT-3) TTGJCWZ FLT3_HUMAN Inhibitor [8], [9]
Protein kinase C gamma (PRKCG) TTRFOXJ KPCG_HUMAN Inhibitor [8], [9]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [10]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Acute myeloid leukaemia
ICD Disease Classification 2A60
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Fms-like tyrosine kinase 3 (FLT-3) DTT FLT3 2.11E-01 -0.05 -0.16
P-glycoprotein 1 (ABCB1) DTP P-GP 9.39E-02 1.07E-01 2.80E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.04E-02 6.29E-02 3.54E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Midostaurin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Midostaurin and Ivosidenib. Acute myeloid leukaemia [2A60] [43]
Arn-509 DMT81LZ Major Increased metabolism of Midostaurin caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [44]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Gilteritinib. Acute myeloid leukaemia [2A60] [45]
Coadministration of a Drug Treating the Disease Different from Midostaurin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Metreleptin DM1NOEK Moderate Increased metabolism of Midostaurin caused by Metreleptin mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [44]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Oliceridine. Acute pain [MG31] [46]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Midostaurin and Ivabradine. Angina pectoris [BA40] [47]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Midostaurin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [48]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Midostaurin and Levalbuterol. Asthma [CA23] [49]
Troleandomycin DMUZNIG Major Decreased metabolism of Midostaurin caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [44]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Midostaurin caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [44]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Eribulin. Breast cancer [2C60-2C6Y] [46]
Talazoparib DM1KS78 Moderate Decreased clearance of Midostaurin due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [50]
Tucatinib DMBESUA Major Decreased metabolism of Midostaurin caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [44]
Palbociclib DMD7L94 Moderate Decreased metabolism of Midostaurin caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [44]
Cabazitaxel DMPAZHC Moderate Decreased clearance of Midostaurin due to the transporter inhibition by Cabazitaxel. Breast cancer [2C60-2C6Y] [47]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Bosutinib. Breast cancer [2C60-2C6Y] [47]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Midostaurin and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [51]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Olodaterol. Chronic obstructive pulmonary disease [CA22] [52]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Vilanterol. Chronic obstructive pulmonary disease [CA22] [49]
Revefenacin DMMP5SI Moderate Decreased clearance of Midostaurin due to the transporter inhibition by Revefenacin. Chronic obstructive pulmonary disease [CA22] [53]
Fidaxomicin DMFP6MV Minor Decreased clearance of Midostaurin due to the transporter inhibition by Fidaxomicin. Clostridium difficile enterocolitis [1A04] [54]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Midostaurin and Pasireotide. Cushing syndrome [5A70] [46]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Osilodrostat. Cushing syndrome [5A70] [47]
Lumacaftor DMCLWDJ Major Increased metabolism of Midostaurin caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [44]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Midostaurin caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [44]
MK-8228 DMOB58Q Moderate Decreased metabolism of Midostaurin caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [44]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Deutetrabenazine. Dystonic disorder [8A02] [55]
Ingrezza DMVPLNC Moderate Additive CNS depression effects by the combination of Midostaurin and Ingrezza. Dystonic disorder [8A02] [56]
Stiripentol DMMSDOY Moderate Decreased metabolism of Midostaurin caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [44]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Midostaurin caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [44]
Tazemetostat DMWP1BH Moderate Increased metabolism of Midostaurin caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [44]
Ripretinib DM958QB Moderate Decreased clearance of Midostaurin due to the transporter inhibition by Ripretinib. Gastrointestinal stromal tumour [2B5B] [54]
Boceprevir DMBSHMF Major Decreased metabolism of Midostaurin caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [44]
Brentuximab vedotin DMWLC57 Moderate Decreased clearance of Midostaurin due to the transporter inhibition by Brentuximab vedotin. Hodgkin lymphoma [2B30] [57]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [58]
Cobicistat DM6L4H2 Major Decreased metabolism of Midostaurin caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [44]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [46]
Teriflunomide DMQ2FKJ Major Additive myelosuppressive effects by the combination of Midostaurin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [59]
BMS-201038 DMQTAGO Moderate Decreased metabolism of Midostaurin caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [44]
Aliskiren DM1BV7W Moderate Decreased clearance of Midostaurin due to the transporter inhibition by Aliskiren. Hypertension [BA00-BA04] [47]
Levamlodipine DM92S6N Moderate Decreased metabolism of Midostaurin caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [44]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Midostaurin caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [44]
Suvorexant DM0E6S3 Moderate Decreased metabolism of Midostaurin caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [44]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Midostaurin and Polyethylene glycol. Irritable bowel syndrome [DD91] [47]
Naloxegol DML0B41 Minor Decreased metabolism of Midostaurin caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [60]
Denosumab DMNI0KO Moderate Additive myelosuppressive effects by the combination of Midostaurin and Denosumab. Low bone mass disorder [FB83] [61]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Midostaurin and Crizotinib. Lung cancer [2C25] [62]
Ceritinib DMB920Z Major Decreased metabolism of Midostaurin caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [44]
PF-06463922 DMKM7EW Moderate Increased metabolism of Midostaurin caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [44]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Midostaurin and Osimertinib. Lung cancer [2C25] [63]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Midostaurin and Selpercatinib. Lung cancer [2C25] [47]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Midostaurin and Lumefantrine. Malaria [1F40-1F45] [54]
Artesunate DMR27C8 Moderate Decreased clearance of Midostaurin due to the transporter inhibition by Artesunate. Malaria [1F40-1F45] [47]
Idelalisib DM602WT Major Decreased metabolism of Midostaurin caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [44]
GDC-0199 DMH0QKA Major Decreased clearance of Midostaurin due to the transporter inhibition by GDC-0199. Mature B-cell leukaemia [2A82] [54]
IPI-145 DMWA24P Moderate Decreased metabolism of Midostaurin caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [44]
Arry-162 DM1P6FR Moderate Decreased clearance of Midostaurin due to the transporter inhibition by Arry-162. Melanoma [2C30] [54]
Trametinib DM2JGQ3 Moderate Decreased clearance of Midostaurin due to the transporter inhibition by Trametinib. Melanoma [2C30] [47]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Midostaurin and Vemurafenib. Melanoma [2C30] [46]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Midostaurin and LGX818. Melanoma [2C30] [64]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Midostaurin caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [47]
Ubrogepant DM749I3 Moderate Decreased clearance of Midostaurin due to the transporter inhibition by Ubrogepant. Migraine [8A80] [65]
Rimegepant DMHOAUG Moderate Decreased clearance of Midostaurin due to the transporter inhibition by Rimegepant. Migraine [8A80] [66]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Midostaurin and Panobinostat. Multiple myeloma [2A83] [67]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Midostaurin and Tecfidera. Multiple sclerosis [8A40] [68]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Midostaurin and Siponimod. Multiple sclerosis [8A40] [54]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Midostaurin and Fingolimod. Multiple sclerosis [8A40] [69]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Midostaurin and Ocrelizumab. Multiple sclerosis [8A40] [70]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Midostaurin and Ozanimod. Multiple sclerosis [8A40] [47]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Midostaurin caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [44]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Entrectinib. Non-small cell lung cancer [2C25] [54]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Rucaparib. Ovarian cancer [2C73] [46]
MK-4827 DMLYGH4 Moderate Decreased clearance of Midostaurin due to the transporter inhibition by MK-4827. Ovarian cancer [2C73] [47]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Triclabendazole. Parasitic worm infestation [1F90] [46]
Abametapir DM2RX0I Moderate Decreased metabolism of Midostaurin caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [71]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Midostaurin and Macimorelin. Pituitary gland disorder [5A60-5A61] [72]
Lefamulin DME6G97 Major Decreased metabolism of Midostaurin caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [73]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Degarelix. Prostate cancer [2C82] [47]
Enzalutamide DMGL19D Major Increased metabolism of Midostaurin caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [44]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Relugolix. Prostate cancer [2C82] [47]
Selexipag DMAHSU0 Moderate Decreased clearance of Midostaurin due to the transporter inhibition by Selexipag. Pulmonary hypertension [BB01] [47]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Midostaurin and Golimumab. Rheumatoid arthritis [FA20] [74]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Midostaurin when combined with Anthrax vaccine. Sepsis [1G40-1G41] [75]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Midostaurin caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [44]
Larotrectinib DM26CQR Moderate Decreased metabolism of Midostaurin caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [44]
LEE011 DMMX75K Moderate Decreased metabolism of Midostaurin caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [44]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [47]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Pitolisant. Somnolence [MG42] [46]
Fostamatinib DM6AUHV Moderate Decreased clearance of Midostaurin due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [76]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Midostaurin due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [77]
Apixaban DM89JLN Moderate Decreased metabolism of Midostaurin caused by Apixaban mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [47]
Brilinta DMBR01X Moderate Decreased metabolism of Midostaurin caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [44]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Midostaurin and Lenvatinib. Thyroid cancer [2D10] [46]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Midostaurin and Cabozantinib. Thyroid cancer [2D10] [47]
Elagolix DMB2C0E Moderate Increased metabolism of Midostaurin caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [44]
Betrixaban DM2C4RF Moderate Decreased clearance of Midostaurin due to the transporter inhibition by Betrixaban. Venous thromboembolism [BD72] [78]
⏷ Show the Full List of 93 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Alpha-tocopherol E00243 14985 Antimicrobial preservative; Antioxidant
Carminic acid E00506 10255083 Colorant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Glycerin E00026 753 Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Hydrogenated polyoxyl 40 castor oil E00662 Not Available Emulsifying agent; Solubilizing agent; Surfactant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Water E00035 962 Solvent
⏷ Show the Full List of 10 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Midostaurin 25 mg capsule 25 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
2 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5702).
4 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Swaminathan R: Magnesium metabolism and its disorders. Clin Biochem Rev. 2003 May;24(2):47-66.
7 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
8 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
9 CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subt... Clin Cancer Res. 2009 Apr 1;15(7):2238-47.
10 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
11 Midostaurin, a novel protein kinase inhibitor for the treatment of acute myelogenous leukemia: insights from human absorption, metabolism, and excretion studies of a BDDCS II drug. Drug Metab Dispos. 2017 May;45(5):540-555.
12 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
13 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
14 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
15 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
16 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
17 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
18 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
19 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
20 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
22 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
23 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
24 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
25 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
26 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
27 Evaluation of differential hypoxic cytotoxicity and electrochemical studies of nitro 5-deazaflavins, Bioorg. Med. Chem. Lett. 5(18):2155-2160 (1995).
28 Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994).
29 Synthesis of bisindolylmaleimide macrocycles, Bioorg. Med. Chem. Lett. 5(18):2093-2096 (1995).
30 Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84.
31 Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2... J Biol Chem. 2007 Nov 9;282(45):33052-63.
32 Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
33 (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H... J Med Chem. 1996 Jul 5;39(14):2664-71.
34 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1807).
35 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
36 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
37 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
38 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
39 Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with ... Blood. 2008 Jun 15;111(12):5663-71.
40 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
41 Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
42 Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93.
43 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
44 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
45 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
46 Canadian Pharmacists Association.
47 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
48 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
49 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
50 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
51 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
52 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
53 Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
54 Cerner Multum, Inc. "Australian Product Information.".
55 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
56 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
57 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
58 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
59 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
60 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
61 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
62 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
63 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
64 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
65 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
66 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
67 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
68 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
69 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
70 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
71 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
72 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
73 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
74 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
75 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
76 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
77 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
78 Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.